Clinical trial
A Phase 2 Proof-of-Concept Study of CSI-Glucagon™ (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism
NCT02937558 is registered in ClinicalTrials.gov with Xeris Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Proof-of-Concept Study of CSI-Glucagon™ (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism
- Lead sponsor
- Xeris Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- October 31, 2018
- Enrollment
- 5 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.